Aidoc raises another $150 million to advance AI in clinical decision-making
New funding backs foundation model designed to transform radiology workflows and reduce diagnostic errors.
Aidoc, a company that has developed an AI system to help medical teams make real-time clinical decisions, has raised $150 million, less than a year after raising a similar amount. To date, the company has raised over half a billion dollars. The current round was led by Growth Equity at Goldman Sachs Alternatives.
Among the company’s investors are General Catalyst, SoftBank Investment Advisors, NVentures (NVIDIA's venture capital arm), Square Peg, TCV, Magma and TLV Partners. In addition to venture capital funds, large U.S. health systems such as Mercy and Hartford HealthCare, as well as Amazon Web Services, have also invested in the company.
The purpose of the new round is to continue developing CARE, the company’s foundation model, which serves as its new technological core. Unlike earlier generations of AI, where each algorithm was trained to identify a single condition (such as a cerebral hemorrhage or a rib fracture), the CARE engine is based on a foundation model trained on tens of millions of medical scans. The model can analyze a scan holistically, identify dozens of findings simultaneously, and interpret their clinical context.
In FDA evaluations, the system demonstrated a sensitivity of 97% and specificity of 98%, significantly reducing false positives. In January 2026, the company received approval from the U.S. Food and Drug Administration for 11 new indications at once based on this model, bringing its total to more than 30 approvals, the highest number in its field.
Over the past year, the company has been promoting the concept of “Agentic Radiology,” aiming to transform AI from a passive identification tool into an active clinical agent. The system is designed to generate an initial draft of a radiologist’s report, reducing time spent on typing and documentation. Instead of searching for a “needle in a haystack,” clinicians are presented with flagged areas for rapid review and confirmation.
Aidoc was founded in 2016 by its CEO Elad Walach, CTO Michael Braginsky, and VP of R&D and CISO Guy Reiner, all three graduates of the IDF’s Talpiot program. The company’s technology is deployed in more than 1,600 medical centers worldwide, including Sheba Medical Center.
Aidoc operates one of the most advanced AI research and development centers in healthcare. Its platform is used in thousands of hospitals globally and in most hospitals in Israel, with FDA-approved tools that provide real-time alerts for life-threatening conditions, including cerebral hemorrhages, aneurysms, fractures, aortic conditions, and pulmonary embolisms.
Earlier this year, CARE received a landmark first FDA clearance for a comprehensive double-digit foundation model-based triage system in clinical imaging. Today, the company analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals.
